By Pete Myers, Environmental Health Sciences
Yesterday Environmental Health News (EHN) started running an extensive investigation of FDA’s willful ignorance of low dose effects of BPA in the 15+ million dollar study called CLARITY BPA. While the focus is explicitly on BPA, it is highly relevant to not only all other bisphenols but also to all endocrine disrupting chemicals. The FDA has bought the story that low-dose non-monotonic effects aren’t real, and chooses not only to use flawed and out of date science to test for safety, but very likely engaged in fraudulent behavior as it chose to ignore its own statistically significant data.
Kudos to Lynn Peeples, the investigative reporter who worked on this for well over a year, and to Brian Bienkowski and Andrew Towl, the creators of the comic strip.
Here’s a link to the series, “Exposed: How willful blindness keeps BPA on shelves and contaminating our bodies,” and here’s a link to a comic strip that captures and distills the tragi-comedy of CLARITY-BPA.
Coincidentally, Vandenberg et al. last week published a peer-reviewed paper that examines apparent malfeasance by the FDA in its use of historical controls in CLARITY-BPA. The paper reveals a deep bias in FDA’s analysis. It is so purposeful it can’t be interpreted a simply incompetence.